mavelertinib (PF-06747775)

Median progression-free survival (90% CI) was 8.1 (5.4-23.3) months. PF-06747775 had a manageable safety profile and the study design highlights important considerations for future anti-EGFR agent development.

P1/2, N=65, Terminated, Pfizer | Phase classification: P2 --> P1/2

Here, we present the first complex crystal structures of mutant EGFR in complex with third-generation inhibitors such as osimertinib and mavelertinib in the presence of simultaneously bound allosteric inhibitors. These structures highlight the possibility of further combinations targeting EGFR and lay the foundation for hybrid inhibitors as next-generation TKIs.

P2; N=65; Terminated; Sponsor: Pfizer; Completed --> Terminated; The study was ended for strategic reasons and changes in the external environment. The safety profile and risk benefit ratio for PF-0674775 remained unchanged.